You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRemoxipride
Accession NumberDB00409  (APRD00316)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionAn antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia. [PubChem]
Structure
Thumb
Synonyms
a-33547
FLA-731
Remoxiprida
Remoxipride
Remoxipridum
Romoxipride
Roxiam
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII0223RD59PE
CAS number80125-14-0
WeightAverage: 371.269
Monoisotopic: 370.089205259
Chemical FormulaC16H23BrN2O3
InChI KeyInChIKey=GUJRSXAPGDDABA-NSHDSACASA-N
InChI
InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1
IUPAC Name
3-bromo-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2,6-dimethoxybenzamide
SMILES
CCN1CCC[[email protected]]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentSalicylamides
Alternative Parents
Substituents
  • M-dimethoxybenzene
  • Dimethoxybenzene
  • 3-halobenzoic acid or derivatives
  • Salicylamide
  • Benzamide
  • Methoxybenzene
  • Phenol ether
  • Benzoyl
  • Anisole
  • Halobenzene
  • Bromobenzene
  • Alkyl aryl ether
  • N-alkylpyrrolidine
  • Aryl halide
  • Aryl bromide
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organobromide
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationRemoxipride is an atypical antipsychotic once used for the treatment of schizophrenia.
PharmacodynamicsRemoxipride, a substituted benzamide, is a selective D2 receptor antagonist. It has been shown to be effective in the treatment of schizophrenia. Some antipsychotics block domapinergic receptors as well as cholinergic, noradrenergic and histaminergic receptors. Remoxipride was developed to act specifically on the dopamine D2 receptor. As a consequence, several undesired side effects can occur. Patients often feel they are not taking any antipsychotic drug. It has a potent affinity for the sigma receptor, but it is unclear whether it is a sigma agonist or antagonist. The contribution of this property to its clinical profile is unknown. Blocking the D2 dopamine receptor is known to cause relapse in patients that have achieved remission from depression, and such blocking also counteracts the effectiveness of SSRI medication.
Mechanism of actionRemoxipride acts as an antagonist at the D2 dopamine receptor. It is believed that overactivity of dopamine systems in the mesolimbic pathway may contribute to the "positive symptoms" of schizophrenia (such as delusions and hallucinations), whereas problems with dopamine function in the mesocortical pathway may be responsible for the "negative symptoms", such as avolition, flat emotional response and alogia. Therefore, by decreasing the levels of dopamine in these pathways, it is thought that remoxipride is able to reduce the symptoms of schizophrenia, particularily the "positive symptoms".
Related Articles
AbsorptionRapidly absorbed. Absolute bioavailability is 90%.
Volume of distributionNot Available
Protein binding89-98%
Metabolism

No active metabolites

Route of eliminationNot Available
Half life4-7 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9705
Caco-2 permeable+0.5835
P-glycoprotein substrateSubstrate0.775
P-glycoprotein inhibitor INon-inhibitor0.674
P-glycoprotein inhibitor IINon-inhibitor0.6462
Renal organic cation transporterNon-inhibitor0.5402
CYP450 2C9 substrateNon-substrate0.868
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.5728
CYP450 1A2 substrateNon-inhibitor0.6776
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5505
Ames testNon AMES toxic0.6906
CarcinogenicityNon-carcinogens0.8373
BiodegradationNot ready biodegradable0.9703
Rat acute toxicity2.8267 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.802
hERG inhibition (predictor II)Inhibitor0.7976
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility74 mg/LNot Available
logP2.10HOEGBERG,T ET AL. 1986
Predicted Properties
PropertyValueSource
Water Solubility0.127 mg/mLALOGPS
logP2.94ALOGPS
logP2.34ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)13.06ChemAxon
pKa (Strongest Basic)8.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area50.8 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity90.56 m3·mol-1ChemAxon
Polarizability36.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US4232037
General ReferencesNot Available
External Links
ATC CodesN05AL04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineRemoxipride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineRemoxipride may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Remoxipride is combined with 7-Nitroindazole.
AbirateroneThe metabolism of Remoxipride can be decreased when combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Remoxipride is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Remoxipride is combined with Alfentanil.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Remoxipride.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Remoxipride.
AmiodaroneThe metabolism of Remoxipride can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Remoxipride.
AmobarbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amperozide.
AmphetamineRemoxipride may decrease the stimulatory activities of Amphetamine.
AripiprazoleThe risk or severity of adverse effects can be increased when Remoxipride is combined with Aripiprazole.
ArtemetherThe metabolism of Remoxipride can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Asenapine.
AtomoxetineThe metabolism of Remoxipride can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Azaperone.
AzelastineRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Remoxipride.
BaclofenThe risk or severity of adverse effects can be increased when Remoxipride is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Benzocaine.
BenzphetamineRemoxipride may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Remoxipride is combined with Benzyl alcohol.
BetaxololThe metabolism of Remoxipride can be decreased when combined with Betaxolol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.
BrimonidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Remoxipride.
BrompheniramineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Remoxipride.
BuprenorphineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Buprenorphine.
BupropionThe metabolism of Remoxipride can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Remoxipride.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Remoxipride.
ButacaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butorphanol.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Remoxipride.
CarbamazepineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carisoprodol.
CelecoxibThe metabolism of Remoxipride can be decreased when combined with Celecoxib.
CetirizineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chloroprocaine.
ChloroquineThe metabolism of Remoxipride can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorphenamine.
ChlorphentermineRemoxipride may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe metabolism of Remoxipride can be decreased when combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Remoxipride can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Remoxipride can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Remoxipride can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cinchocaine.
CitalopramThe risk or severity of adverse effects can be increased when Remoxipride is combined with Citalopram.
ClemastineThe metabolism of Remoxipride can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clidinium.
ClobazamThe metabolism of Remoxipride can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Remoxipride is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clorazepate.
ClotrimazoleThe metabolism of Remoxipride can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Remoxipride can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clozapine.
CobicistatThe serum concentration of Remoxipride can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Remoxipride.
CyclizineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Remoxipride.
CyproheptadineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Remoxipride.
DapoxetineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dapoxetine.
DarifenacinThe metabolism of Remoxipride can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Remoxipride can be increased when it is combined with Darunavir.
DelavirdineThe metabolism of Remoxipride can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Remoxipride is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Remoxipride.
DesloratadineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Remoxipride.
DetomidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dexmedetomidine.
DextroamphetamineRemoxipride may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Remoxipride.
DextromoramideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Remoxipride.
DihydroetorphineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Remoxipride can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Remoxipride.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.
DoxylamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Remoxipride is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.
DronedaroneThe metabolism of Remoxipride can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Remoxipride.
DyclonineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Remoxipride is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Remoxipride is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Remoxipride.
EliglustatThe metabolism of Remoxipride can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Remoxipride.
EntacaponeThe risk or severity of adverse effects can be increased when Remoxipride is combined with Entacapone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Remoxipride.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Remoxipride.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Remoxipride.
EscitalopramThe risk or severity of adverse effects can be increased when Remoxipride is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Remoxipride.
EthanolRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Remoxipride.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remoxipride.
EthosuximideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Remoxipride.
EtoperidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Remoxipride.
FexofenadineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Remoxipride.
GabapentinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Remoxipride is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Remoxipride is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Halazepam.
HaloperidolThe metabolism of Remoxipride can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Remoxipride.
Hydroxyamphetamine hydrobromideRemoxipride may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.
HydroxyzineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Remoxipride.
IndalpineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Indalpine.
IndinavirThe metabolism of Remoxipride can be decreased when combined with Indinavir.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Remoxipride.
IsofluraneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Isoflurane.
IsoniazidThe metabolism of Remoxipride can be decreased when combined with Isoniazid.
KetamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ketobemidone.
KetoconazoleThe metabolism of Remoxipride can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Remoxipride.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Remoxipride.
LisdexamfetamineRemoxipride may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Remoxipride.
LithiumThe risk or severity of adverse effects can be increased when Remoxipride is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Remoxipride is combined with Lofentanil.
LopinavirThe metabolism of Remoxipride can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Remoxipride.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Remoxipride.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Remoxipride.
Lu AA21004The risk or severity of adverse effects can be increased when Remoxipride is combined with Lu AA21004.
LumefantrineThe metabolism of Remoxipride can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Remoxipride.
MeclizineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Remoxipride is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Melperone.
MephentermineRemoxipride may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Remoxipride.
MequitazineRemoxipride may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Remoxipride.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methadyl Acetate.
MethamphetamineRemoxipride may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenobarbital.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Remoxipride.
MetoprololThe metabolism of Remoxipride can be decreased when combined with Metoprolol.
MetyrosineRemoxipride may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Remoxipride.
MidazolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Midazolam.
MilnacipranThe risk or severity of adverse effects can be increased when Remoxipride is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.
MirabegronThe metabolism of Remoxipride can be decreased when combined with Mirabegron.
MirtazapineRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Remoxipride.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Remoxipride.
MolindoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Remoxipride.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.
NabiloneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Nalbuphine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Remoxipride.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Remoxipride.
NevirapineThe metabolism of Remoxipride can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Remoxipride can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Remoxipride can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Remoxipride.
OlanzapineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Remoxipride is combined with Opium.
OrphenadrineRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Remoxipride.
OsanetantThe risk or severity of adverse effects can be increased when Remoxipride is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Paliperidone.
PanobinostatThe metabolism of Remoxipride can be decreased when combined with Panobinostat.
ParaldehydeRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Remoxipride.
ParoxetineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Remoxipride can be decreased when it is combined with Peginterferon alfa-2b.
PentazocineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Remoxipride.
PerampanelThe risk or severity of adverse effects can be increased when Remoxipride is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Remoxipride is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Remoxipride.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Remoxipride.
PhenobarbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Phenoxyethanol.
PhentermineRemoxipride may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pomalidomide.
PramipexoleRemoxipride may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Remoxipride.
PrilocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Remoxipride.
ProchlorperazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Prochlorperazine.
PromazineThe metabolism of Remoxipride can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Remoxipride.
ProparacaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Remoxipride.
PSD502The risk or severity of adverse effects can be increased when Remoxipride is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Quetiapine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Remoxipride.
QuinidineThe metabolism of Remoxipride can be decreased when combined with Quinidine.
QuinineThe metabolism of Remoxipride can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ramelteon.
RanolazineThe metabolism of Remoxipride can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Remoxipride.
RemifentanilThe risk or severity of adverse effects can be increased when Remoxipride is combined with Remifentanil.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Remoxipride.
RisperidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Risperidone.
RitonavirThe metabolism of Remoxipride can be decreased when combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Remoxipride.
RolapitantThe metabolism of Remoxipride can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Romifidine.
RopiniroleRemoxipride may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Remoxipride can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Remoxipride.
RotigotineRemoxipride may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Remoxipride.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Remoxipride is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Secobarbital.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Remoxipride.
SertindoleThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sufentanil.
SulpirideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Remoxipride.
SuvorexantThe risk or severity of adverse effects can be increased when Remoxipride is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Remoxipride.
TasimelteonThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Remoxipride.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Remoxipride.
TerbinafineThe metabolism of Remoxipride can be decreased when combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Remoxipride.
TetracaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tetrodotoxin.
ThalidomideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Remoxipride.
ThiamylalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tiagabine.
TiclopidineThe metabolism of Remoxipride can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tiletamine.
TipranavirThe metabolism of Remoxipride can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Remoxipride.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Remoxipride.
TrazodoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Remoxipride.
TriprolidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Remoxipride.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Remoxipride.
VigabatrinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zimelidine.
ZiprasidoneThe metabolism of Remoxipride can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Remoxipride.
ZolpidemThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  2. Lang AE, Sandor P, Duff J: Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45. [PubMed:8665533 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Seeman P, Corbett R, Van Tol HH: Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology. 1997 Feb;16(2):93-110; discussion 111-35. [PubMed:9015795 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Christian AJ, Goodwin AK, Baker LE: Antagonism of the discriminative stimulus effects of (+)-7-OH-DPAT by remoxipride but not PNU-99194A. Pharmacol Biochem Behav. 2001 Mar;68(3):371-7. [PubMed:11325388 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Seeman P, Corbett R, Van Tol HH: Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology. 1997 Feb;16(2):93-110; discussion 111-35. [PubMed:9015795 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Opioid receptor activity
Specific Function:
Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. Involved in the regulation of different receptors it plays a role in BDNF signaling and EGF signaling. Also regulates ion channels like the potassium channel and could modulate neurotransmitt...
Gene Name:
SIGMAR1
Uniprot ID:
Q99720
Molecular Weight:
25127.52 Da
References
  1. Lang A, Soosaar A, Koks S, Volke V, Bourin M, Bradwejn J, Vasar E: Pharmacological comparison of antipsychotic drugs and sigma-antagonists in rodents. Pharmacol Toxicol. 1994 Sep-Oct;75(3-4):222-7. [PubMed:7800667 ]
  2. Okuyama S: [Atypical antipsychotic profiles of sigma receptor ligands]. Nihon Yakurigaku Zasshi. 1999 Jul;114(1):13-23. [PubMed:10562961 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23